AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Outlook Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00469JRM1
0.52▼ 0.04 (-7.84%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.56
Day's Range
0.51 – 0.56
52-Week Range
0.16 – 2.54
Volume
3.1M
Avg Volume
4.3M
Share Statistics
Shares Outstanding
Employees
17
Exchange
XNAS
Listed
2016-05-13
Share count as of August 14, 2026

Outlook Therapeutics, Inc. Common Stock (OTLK) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Outlook Therapeutics, Inc. Common Stock (OTLK)
What is Outlook Therapeutics, Inc. Common Stock's Market Cap?
Outlook Therapeutics, Inc. Common Stock's Market Cap is $126.4M, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's Enterprise Value?
Outlook Therapeutics, Inc. Common Stock's Enterprise Value is $144.6M, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's Price / Sales?
Outlook Therapeutics, Inc. Common Stock's Price / Sales is 89.4×, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's EV / Revenue?
Outlook Therapeutics, Inc. Common Stock's EV / Revenue is 102.3×, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's EV / EBITDA?
Outlook Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's Revenue (TTM)?
Outlook Therapeutics, Inc. Common Stock's Revenue (TTM) is $1.4M, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's Net Income (TTM)?
Outlook Therapeutics, Inc. Common Stock's Net Income (TTM) is -$61.1M, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's EBITDA?
Outlook Therapeutics, Inc. Common Stock's EBITDA is -$55.5M, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Outlook Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.25, based on as-reported figures from SEC (XBRL) filings.
What is Outlook Therapeutics, Inc. Common Stock's EBITDA Margin?
Outlook Therapeutics, Inc. Common Stock's EBITDA Margin is -3928.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · OTLKAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Consolidated Statements of Operations
Revenues, net
Cost of revenues
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Loss from operations
Loss (Gain) on equity method investment
Interest (income) expense, net
Loss from change in fair value of promissory notes
Warrant inducement expenses———
(Gain) loss from change in fair value of warrant liability
(Gain) loss on extinguishment of debt——
Net loss before income taxes—
Net loss
Loss per share of common stock, basic (in dollars per share)
Loss per share of common stock, diluted (in dollars per share)